Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
CC transcript
ALNYLAM PHARMACEUTICALS, INC. (ALNY) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis"
09/28/2023 8-K Quarterly results
08/07/2023 4 Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 4,518 shares @ $0
Granted 3,109 shares @ $0
Sold 658 shares @ $184.7, valued at $121.5k
Sold 1,593 shares @ $185.54, valued at $295.6k
Sold 945 shares @ $186.39, valued at $176.1k
Sold 86 shares @ $187.37, valued at $16.1k
Sold 15 shares @ $188.4, valued at $2.8k
Sold 164 shares @ $189.31, valued at $31k
Sold 3,112 shares @ $183.58, valued at $571.3k
Sold 814 shares @ $184.65, valued at $150.3k
Sold 240 shares @ $185.32, valued at $44.5k
08/07/2023 4 Poulton Jeffrey V. (EVP, CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 4,518 shares @ $0
Granted 3,109 shares @ $0
Sold 658 shares @ $184.7, valued at $121.5k
Sold 1,593 shares @ $185.54, valued at $295.6k
Sold 944 shares @ $186.39, valued at $176k
Sold 86 shares @ $187.37, valued at $16.1k
Sold 15 shares @ $188.4, valued at $2.8k
Sold 164 shares @ $189.31, valued at $31k
08/07/2023 4 Greenstreet Yvonne (CEO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 5,082 shares @ $0
Granted 3,859 shares @ $0
Sold 771 shares @ $184.7, valued at $142.4k
Sold 1,869 shares @ $185.54, valued at $346.8k
Sold 1,107 shares @ $186.39, valued at $206.3k
Sold 101 shares @ $187.37, valued at $18.9k
Sold 17 shares @ $188.4, valued at $3.2k
Sold 192 shares @ $189.31, valued at $36.3k
08/07/2023 4 Vaishnaw Akshay (President) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 5,082 shares @ $0
Granted 3,859 shares @ $0
Sold 771 shares @ $184.7, valued at $142.4k
Sold 1,869 shares @ $185.54, valued at $346.8k
Sold 1,107 shares @ $186.39, valued at $206.3k
Sold 101 shares @ $187.37, valued at $18.9k
Sold 17 shares @ $188.4, valued at $3.2k
Sold 192 shares @ $189.31, valued at $36.3k
08/07/2023 144 Form 144 - Report of proposed sale of securities:
08/04/2023 4 BONNEY MICHAEL W (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Sold 300 shares @ $181.08, valued at $54.3k
Sold 500 shares @ $182.45, valued at $91.2k
Sold 560 shares @ $183.75, valued at $102.9k
Sold 1,535 shares @ $184.89, valued at $283.8k
Sold 1,714 shares @ $185.99, valued at $318.8k
Sold 1,389 shares @ $187.04, valued at $259.8k
Sold 450 shares @ $187.71, valued at $84.5k
Exercised 22,477 restricted stock units @ $0
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Letter Agreement, between Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D",
"Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity"
07/26/2023 8-K Quarterly results
06/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO ® for the Treatment of the Cardiomyopathy of ATTR Amyloidosis"
05/23/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/19/2023 4 PYOTT DAVID E I (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/19/2023 4 Sigal Charles Elliott (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/19/2023 4 BRANDICOURT OLIVIER (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/19/2023 4 HAMBURG MARGARET A (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/19/2023 4 Reitan Colleen F (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/19/2023 4 SCHULMAN AMY W (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/19/2023 4 Ausiello Dennis A (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/19/2023 4 Fanucci Marsha (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/19/2023 4 BONNEY MICHAEL W (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/19/2023 4 SHARP PHILLIP A (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,454 options to buy @ $189.87, valued at $655.8k
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/28/2023 4 Greenstreet Yvonne (CEO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 16,952 shares @ $0
Sold 628 shares @ $193.18, valued at $121.3k
Sold 2,898 shares @ $193.93, valued at $562k
Sold 3,225 shares @ $194.94, valued at $628.7k
Sold 331 shares @ $195.65, valued at $64.8k
Sold 533 shares @ $197.08, valued at $105k
04/28/2023 4 Poulton Jeffrey V. (EVP, CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,277 shares @ $0
Sold 81 shares @ $193.18, valued at $15.6k
Sold 372 shares @ $193.93, valued at $72.1k
Sold 414 shares @ $194.94, valued at $80.7k
Sold 42 shares @ $195.65, valued at $8.2k
Sold 68 shares @ $197.08, valued at $13.4k
04/28/2023 4 Tanguler Tolga (EVP, Chief Commercial Officer) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 3,277 shares @ $0
Sold 122 shares @ $193.18, valued at $23.6k
Sold 562 shares @ $193.93, valued at $109k
Sold 625 shares @ $194.94, valued at $121.8k
Sold 64 shares @ $195.65, valued at $12.5k
Sold 103 shares @ $197.08, valued at $20.3k
04/28/2023 4 Vaishnaw Akshay (President) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 5,312 shares @ $0
Sold 197 shares @ $193.18, valued at $38.1k
Sold 910 shares @ $193.93, valued at $176.5k
Sold 1,013 shares @ $194.94, valued at $197.5k
Sold 104 shares @ $195.65, valued at $20.3k
Sold 168 shares @ $197.08, valued at $33.1k
04/28/2023 4 Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns: Granted 4,294 shares @ $0
Sold 151 shares @ $193.18, valued at $29.2k
Sold 700 shares @ $193.93, valued at $135.8k
Sold 779 shares @ $194.94, valued at $151.9k
Sold 80 shares @ $195.65, valued at $15.7k
Sold 129 shares @ $197.08, valued at $25.4k
Sold 204 shares @ $195.46, valued at $39.9k
Sold 103 shares @ $196.62, valued at $20.3k
Sold 715 shares @ $198.03, valued at $141.6k
Sold 385 shares @ $199.54, valued at $76.8k
Sold 955 shares @ $200.35, valued at $191.3k
04/28/2023 144 Form 144 - Report of proposed sale of securities:
04/03/2023 ARS Form ARS - Annual Report to Security Holders:
04/03/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/03/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy